A5354/EARLIER: Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection . . . Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses

Study Location:

Washington

Topic:

Clinicaltrials.gov Link:

https://clinicaltrials.gov/ct2/show/NCT02859558?term=ACTG+5354&rank=1

Coordinator:

Anna Wimpleberg

Enrollment:

Open

Trial Period:

Ongoing

This study will include people who have very recently been infected with HIV and will start anti-HIV (antiretroviral) drugs right away to see how this may change HIV’s impact on the body. 

This study is trying to find out if starting antiretroviral drugs very early in HIV infection will change the following:

  • Limit the virus from getting into hidden areas of the body (“reservoirs”).
  • Change how the immune system helps to control the virus.

Men and women who:

  • Are at least 18 years old
  • Have had certain lab tests done that confirm very early HIV infection
  • Are willing to take antiretroviral drugs right away to treat HIV.

Categories

Location
Topic

Clinical Trials

P2001 (DAIDS ID 12026): Evaluating the Pharmacokinetics,...

TB is a major cause of illness and death in women of reproductive age. Pregnant and postpartum women with latent TB are at...

Read More

A5361s: Pitavastatin to REduce Physical Function Impairment...

A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants...

Read More

A5322: Long-Term Follow-up of Older HIV-infected Adults in...

The A5322 protocol is a long-term observational study, with a planned series of analyses of data to be collected from an...

Read More

A5354/EARLIER: Effect of Antiretroviral Treatment Initiated...

This study will include people who have very recently been infected with HIV and will start anti-HIV (antiretroviral) drugs...

Read More

HPTN083: A Phase 2b/3 Double Blind Safety and Efficacy Study...

HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for...

Read More